The marker in question is called DOPA decarboxylase (DCC). In the current study, DCC was found to be elevated in individuals with Parkinson’s disease as well as in people with other diseases that result in dopamine deficiency in the brain. However, the marker was normal in other brain diseases such as Alzheimer’s disease. The researchers even noticed that DCC was elevated in individuals with Parkinson’s many years before they developed any symptoms.
Salipro partners with Icosagen to develop monoclonal antibody therapies – Pharmaceutical Technology
Monoclonal antibodies have been identified by GlobalData as a key innovation area for cancer therapy, with Johnson & Johnson being the leading patent filer in
October 10, 2023